Avalyn Pharma Inc (NASDAQ:AVLN) Q3 Loss Narrower Than Expected as 2027 Pipeline Catalysts Remain in Focus
Avalyn: Q3 Earnings Snapshot
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma Q3 EPS $(0.67) Beats $(0.75) Estimate
Avalyn Pharma Inc. (AVLN) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Avalyn to Present at Upcoming Investor Conferences
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.